TG Therapeutics Inc
TGTX28.860USD
+1.100+3.96%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
4.48BMarket Cap
9.43P/E TTM
More Details of TG Therapeutics Inc Company
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
TG Therapeutics Inc Info
Ticker SymbolTGTX
Company nameTG Therapeutics Inc
IPO dateDec 14, 1995
CEOWeiss (Michael S)
Number of employees338
Security typeOrdinary Share
Fiscal year-endDec 14
Address3020 Carrington Mill Blvd., Suite 475
CityMORRISVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27560-5435
Phone18775758489
Websitehttps://www.tgtherapeutics.com/
Ticker SymbolTGTX
IPO dateDec 14, 1995
CEOWeiss (Michael S)
Company Executives of TG Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
+622000.00%
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
+90000.00%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+14718.00%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
-5000.00%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+14718.00%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
-43197.00%
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
-20852.00%
Name
Name/Position
Position
Shareholding
Change
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
+622000.00%
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
+90000.00%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+14718.00%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
-5000.00%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+14718.00%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
-43197.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q1
FY2024
By BusinessUSD
Name
Revenue
Proportion
Total product revenue, net
159.32M
98.52%
License, milestone, royalty and other revenue
2.39M
1.48%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Total product revenue, net
159.32M
98.52%
License, milestone, royalty and other revenue
2.39M
1.48%
Shareholding Stats
Updated: Wed, Feb 4
Updated: Wed, Feb 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.86%
The Vanguard Group, Inc.
9.95%
Weiss (Michael S)
6.16%
State Street Investment Management (US)
5.10%
ClearBridge Investments, LLC
2.93%
Other
64.00%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.86%
The Vanguard Group, Inc.
9.95%
Weiss (Michael S)
6.16%
State Street Investment Management (US)
5.10%
ClearBridge Investments, LLC
2.93%
Other
64.00%
Shareholder Types
Shareholders
Proportion
Investment Advisor
35.81%
Investment Advisor/Hedge Fund
17.27%
Individual Investor
7.21%
Hedge Fund
7.06%
Research Firm
3.06%
Pension Fund
1.22%
Bank and Trust
0.39%
Family Office
0.22%
Sovereign Wealth Fund
0.06%
Other
27.71%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
729
103.02M
64.89%
-17.74M
2025Q3
698
101.46M
63.91%
-17.24M
2025Q2
693
115.94M
73.03%
-21.56M
2025Q1
704
116.82M
73.80%
-25.76M
2024Q4
657
113.87M
72.65%
-36.14M
2024Q3
598
117.83M
76.11%
-20.28M
2024Q2
544
109.58M
70.90%
-28.91M
2024Q1
535
105.41M
68.45%
-29.01M
2023Q4
542
104.64M
69.13%
-36.73M
2023Q3
552
104.67M
69.33%
-30.54M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
18.83M
11.86%
-301.01K
-1.57%
Sep 30, 2025
The Vanguard Group, Inc.
15.49M
9.75%
-288.02K
-1.83%
Sep 30, 2025
Weiss (Michael S)
9.16M
5.77%
-4.67M
-33.77%
Nov 05, 2025
State Street Investment Management (US)
8.10M
5.1%
+482.38K
+6.33%
Sep 30, 2025
ClearBridge Investments, LLC
4.64M
2.93%
+1.59M
+52.15%
Sep 30, 2025
Soleus Capital Management, L.P.
3.84M
2.42%
+1.60M
+71.34%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.44M
2.17%
-46.54K
-1.33%
Sep 30, 2025
Congress Asset Management Company, LLP
1.00M
0.63%
+1.00M
--
Nov 30, 2025
Hood River Capital Management LLC
1.55M
0.98%
-14.72K
-0.94%
Sep 30, 2025
Pictet Asset Management Ltd.
1.61M
1.01%
-297.94K
-15.62%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco S&P SmallCap Health Care ETF
2.89%
State Street SPDR S&P Biotech ETF
1.93%
Virtus LifeSci Biotech Products ETF
1.49%
Invesco S&P SmallCap 600 Pure Growth ETF
1.44%
Invesco S&P SmallCap Momentum ETF
1.4%
Direxion Daily S&P Biotech Bull 3X Shares
1.11%
State Street SPDR S&P 600 Small Cap Growth ETF
0.65%
First Trust NASDAQ Pharmaceuticals ETF
0.63%
Principal U.S. Small-Cap ETF
0.62%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.61%
View more
Invesco S&P SmallCap Health Care ETF
Proportion2.89%
State Street SPDR S&P Biotech ETF
Proportion1.93%
Virtus LifeSci Biotech Products ETF
Proportion1.49%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.44%
Invesco S&P SmallCap Momentum ETF
Proportion1.4%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.11%
State Street SPDR S&P 600 Small Cap Growth ETF
Proportion0.65%
First Trust NASDAQ Pharmaceuticals ETF
Proportion0.63%
Principal U.S. Small-Cap ETF
Proportion0.62%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.61%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
